focus -WSS

focus

author：leisure time 2025-09-03 03:27:12 - browse：6

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Can sheer will power keep patients alive in their dying hours?

WSS

Albert Bourla of Pfizer: worst biopharma CEO of 2023

What it's like to live with paralysis for one psychologist

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Drinking less cuts risk of oral cavity, esophageal cancer: Report

CDC Director Mandy Cohen on transparency, trust, and health

New Alzheimer's drugs heat up race for early detection blood tests

focus

focus

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

The battle over 'scope creep' and who gets to be called 'doctor'

Novavax promises a turnaround & Lilly roils the obesity market

Biogen says it will cut costs by $700 million, slash 1,000 jobs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

David Ricks of Eli Lilly: best biopharma CEO of 2023

The high cost of giving birth even with insurance

Will the FTC rein in IQVIA's health data empire?

Bright Health sells Medicare Advantage business to Molina

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

explore

SNAP should offer more nutrition education

The battle over 'scope creep' and who gets to be called 'doctor'

New lawsuit accuses health insurer Cigna of denying claims in bulk

Editas, Vertex strike deal on CRISPR

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

hotspot

leisure time

knowledge

explore